Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis
Objective To examine healthcare resource utilisation (HRU) and direct medical costs for patients with diabetic macular oedema (DME) treated with antivascular endothelial growth factor (anti-VEGF) in Korea by comparing with those for (1) patients with diabetes mellitus (DM) without retinopathy and (2...
Main Authors: | Hyesung Lee, Dongwon Yoon, Yeonkyung Lee, Jae Hui Kim, Donghyun Jee |
---|---|
Format: | Article |
Language: | English |
Published: |
BMJ Publishing Group
2020-12-01
|
Series: | BMJ Open |
Online Access: | https://bmjopen.bmj.com/content/10/12/e042484.full |
Similar Items
-
Use of antivascular endothelial growth factor for diabetic macular edema
by: Rushmia Karim, et al.
Published: (2010-05-01) -
Comparing vision and macular thickness in neovascular age-related macular degeneration, diabetic macular oedema and retinal vein occlusion patients treated with intravitreal antivascular endothelial growth factor injections in clinical practice
by: Rajya L Gurung, et al.
Published: (2021-07-01) -
Antivascular Endothelial Growth Factor Agents for Neovascular Age-Related Macular Degeneration
by: Ilias Zampros, et al.
Published: (2012-01-01) -
Resistance to antivascular endothelial growth factor treatment in age-related macular degeneration
by: Tranos P, et al.
Published: (2013-06-01) -
Cystoid macular oedema
by: Singh Daljit
Published: (1983-01-01)